recurrent gastric cancer
Showing 1 - 25 of >10,000
Nivolumab Plus Chemotherapy in Untreated Advanced/Recurrent
Active, not recruiting
- Stomach Neoplasms
-
Minato-ku, Tokyo, JapanLocal Institution
Apr 12, 2022
Gastric Cancer Trial in Shanghai (NK510, Tislelizumab,atezolizumab or Trastuzumab)
Enrolling by invitation
- Gastric Cancer
- NK510
- Tislelizumab，atezolizumab or Trastuzumab
-
Shanghai, ChinaShanghai Tenth People's Hospital
Oct 22, 2023
Gastric Cancer, Gastroesophageal-junction Cancer Trial (Tcrx T cell)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tcrx T cell
- (no location specified)
Jul 21, 2022
Gastric Cancer, Gastroesophageal Junction Cancer Trial in Seoul (afatinib, paclitaxel)
Completed
- Gastric Cancer
- Gastroesophageal Junction Cancer
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System, Yonsei Canc
Jan 26, 2023
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
Active, not recruiting
- Adenocarcinoma of the Gastroesophageal Junction
- +12 more
- copper Cu 64-DOTA-trastuzumab
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer Trial in Seoul (autologous activated T
Recruiting
- Relapsed or Advanced Gastric Adenocarcinoma
- Gastro-esophageal Junction Cancer
- autologous activated T lymphocyte
-
Seoul, Korea, Republic ofGangnam Severacen Hospital
Sep 15, 2021
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
HER2-positive Gastric Cancer Trial (HLX10, Trastuzumab and Chemotherapy)
Not yet recruiting
- HER2-positive Gastric Cancer
- HLX10, Trastuzumab and Chemotherapy
- (no location specified)
Mar 28, 2022
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)
Recruiting
- Gastroesophageal Junction (GEJ) Cancers
- Advanced HNSCC
- N-803
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Safety and Efficacy of Trastuzumab BS
Not yet recruiting
- Gastric Cancer
- TRASTUZUMAB BS
- (no location specified)
Dec 19, 2022
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
Metastatic or Recurrent Gastric Adenocarcinoma Trial in Nanjing (Envafolimab, Oxaliplatin, S1)
Recruiting
- Metastatic or Recurrent Gastric Adenocarcinoma
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Institute & Hospital
Apr 19, 2022
Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)
Not yet recruiting
- Recurrent/Advanced Gastric Cancer
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Aug 22, 2022
Solid Tumor, Stomach Cancer Trial in Seongnam-si, Seoul (Alpelisib, Paclitaxel)
Recruiting
- Solid Tumor
- Stomach Cancer
-
Seongnam-si, Gyeonggi-do, Korea, Republic of
- +1 more
Aug 21, 2021
Stomach Tumor Trial in Chengdu (Capeox regimen combined with Sintilimab and Bevacizumab)
Not yet recruiting
- Stomach Neoplasm
- Capeox regimen combined with Sintilimab and Bevacizumab
-
Chengdu, ChinaLiu Ming
Nov 28, 2022
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in
Active, not recruiting
- Metastatic Esophageal Carcinoma
- +12 more
- Olaparib
- Ramucirumab
-
Corona, California
- +31 more
Aug 9, 2022
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive NSCLC Trial (XMT-2056)
Not yet recruiting
- HER2-positive Breast Cancer
- +4 more
- (no location specified)
Aug 23, 2022
Gastric Adenocarcinoma, GastroEsophageal Cancer Trial in Orange (Cabozantinib, Pembrolizumab)
Recruiting
- Gastric Adenocarcinoma
- GastroEsophageal Cancer
-
Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
Apr 4, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Kashiwa (Regorafenib,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Regorafenib
- +3 more
-
Kashiwa, Chiba, JapanNational Cancer Center Hospital East
May 23, 2022
Malignant Abdominal Tumor, Malignant Pelvic Tumor, Recurrent Colon Carcinoma Trial in Rochester (Cisplatin, Cytoreductive
Recruiting
- Malignant Abdominal Neoplasm
- +26 more
- Cisplatin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 5, 2023
Gastric Cancer Trial in Wuhan (Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1)
Recruiting
- Gastric Cancer
- Albumin-bound Paclitaxel plus S-1
- Oxaliplatin plus S-1
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 3, 2022
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in France
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Trifluridine/Tipiracil
- +2 more
-
Amiens, France
- +20 more
Jul 26, 2022
Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +
Recruiting
- Melanoma
- +14 more
- LITT + Pembrolizumab
-
Gainesville, Florida
- +1 more
Aug 22, 2022